COVID-19 non-medical therapy
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 non-medical therapy On the Web |
|
American Roentgen Ray Society Images of COVID-19 non-medical therapy |
|
Risk calculators and risk factors for COVID-19 non-medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Robert G. Badgett, M.D.[2],
Overview
COVID-19 is an inflammatory hypercytokinemia disease. The aim of therapy is prevention of viral replication and controlling the inflammatory process. On February 09, 2021 FDA approved emergency use authorization of monoclonal antibodies including bamlanivimab and etesevimab for mild to moderate covid-19 patients who are high risk for progression of disease ( age > 65years, medical comorbidities).
Current Non-Medical treatment
These treatments focus on long COVID syndrome:
References
- ↑ Liu Z, Qiao D, Xu Y, Zhao W, Yang Y, Wen D; et al. (2021). "The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial". J Med Internet Res. 23 (5): e26883. doi:10.2196/26883. PMC 8128049 Check
|pmc=value (help). PMID 33900931 Check|pmid=value (help). - ↑ Li J, Li X, Jiang J, Xu X, Wu J, Xu Y; et al. (2020). "The Effect of Cognitive Behavioral Therapy on Depression, Anxiety, and Stress in Patients With COVID-19: A Randomized Controlled Trial". Front Psychiatry. 11: 580827. doi:10.3389/fpsyt.2020.580827. PMC 7661854 Check
|pmc=value (help). PMID 33192723 Check|pmid=value (help).